Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation
Empagliflozin and dapagliflozin initiators had no differences in 6-year cardiovascular outcomes in adults with treated type 2 diabetes with or without coexisting atherosclerotic cardiovascular disease or HF.
Authors
- Sean Hennessy (ORCID: https://orcid.org/0000-0003-4726-9413)
- Timothy L. Lash (ORCID: https://orcid.org/0000-0002-5240-5195)
- Morten Schmidt (ORCID: https://orcid.org/0000-0002-4935-4059)
- Anthony Matthews (ORCID: https://orcid.org/0000-0002-1290-271X)
- Kasper Bonnesen (ORCID: https://orcid.org/0000-0002-8626-2372)
- Reimar W. Thomsen (ORCID: https://orcid.org/0000-0001-9135-3474)
- Diana Hedevang Christensen (ORCID: https://orcid.org/0000-0002-2693-5651)
- Uffe Heide‐Jørgensen (ORCID: https://orcid.org/0000-0002-8407-4618)
- Lars Pedersen (ORCID: https://orcid.org/0000-0002-9341-3888)
Institutions
- Emory University (US)
- Aarhus University (DK)
- Aarhus University Hospital (DK)
- Karolinska Institutet (SE)
- North Denmark Region (DK)
- University of Pennsylvania (US)
Publication Details
- Journal
- Circulation
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1161/circulationaha.124.068613
- Citations
- 17
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.08